CalciMedica, Inc. CALC 深 沪
已收盘 08-07 16:00:00 美东时间
0.6875
-0.024
-3.44%
华盛通- 最 高0.7183
- 今 开0.7125
- 成交量 38.12万股
- 最 低 0.68
- 昨 收 0.712
- 总市值 2113.13万
- 52周最高 7.20
- 市盈率 静 --
- 换手率 1.24%
- 52周最低 0.4606
- 委 比 1.96%
- 总股本 3073.64万
- 历史最高 8.59
- 量 比 0.85
- 振 幅 5.38%
- 历史最低 0.4606
- 每 手 1
- 风险率 1.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora
CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that the U.S. Food ...
06-24 19:05
CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $(0.28) by 207.14 percent. This is a 183.33 percent increase over losses of $(0.36) per share from the
05-12 19:20
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Fr...
03-21 05:05
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10
Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and lowers the price target from $20 to $10.
03-06 01:55
CalciMedica shares are trading higher. The company reported Q4 financial results.
CalciMedica shares are trading higher. The company reported Q4 financial result...
03-04 02:28
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
CalciMedica Q4 EPS $(0.69) Misses $(0.42) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 65.47 percent. This is a 102.94 percent decrease over losses of $(0.34) per share from
03-03 20:36
HC Wainwright & Co. Downgrades CalciMedica to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades CalciMedica (NASDAQ:CALC) from Buy to Neutral.
01-29 19:43
CalciMedica Discontinued Its Phase 2 KOURAGE Trial Of Auxora For Stage 2 Or Stage 3 Acute Kidney Injury With Associated Acute Hypoxemic Respiratory Failure, Following A Recommendation From The Trial's Independent Data Monitoring Committee
During a prescheduled interim data review, the IDMC identified a safety concern that, in its view, warrants reevaluation of the study design, particularly with respect to patient enrollment criteria. There were no deaths
01-28 20:04
